0625/26SCR019-18/R12RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
3
Erika Hamilton, MD
SCRI
Media Outlet Date Article / Coverage
Breast Cancers
Today
6/15/26 HER2CLIMB-05 Update: A Step Forward in Tailored HER2+
Care | Docwire News
Breast Cancers
Today
6/22/26 ASCO 2026 Brings Wins in Personalized Medicine for Breast
Cancer, Tailoring Treatment to the Individual Patient, and In
Supportive Care
Authored by Sarah Premji, MD, Mythili Shastry, PhD,
Chelsea Goodenough, PhD, Erika Hamilton, MD
Cancer Nursing
Today
6/22/26 Targeting CDH6: A New ADC Approach in Gynecologic
Cancer
MedPage Today 6/16/26 Maintenance Regimens Expand in HER2-Positive Metastatic
Breast Cancer
OncLive 5/6/26 ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read
up on the Insights to Know Before You Go
OncLive 5/7/26 ASCO 2026 TNBC Deep Dive: Breast Cancer Experts
Preview Practice-Informing Studies
OncLive 5/21/26 Survival Gains Confirmed: Full KEYNOTE-225 Data Set
to Redefine Treatment Standards in Early-Stage TNBC at
ASCO 2026
Oncology Education 6/3/26 ASCO® 2026 Highlights: Presenter Vignette – Erika Hamilton
Targeted Oncology 6/2/26 Tucatinib Maintenance Improves PFS Across Key
Subgroups in HER2+ MBC
Targeted Oncology 6/12/26 Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+
Breast Cancer
The ASCO Post 6/4/26 Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic
Breast Cancer: Maintenance Therapy Comparison
VJOncology 6/8/26 Breast Cancer Updates at ASCO 2026: KEYNOTE-522,
SERENA-6, and More
VJOncology 6/8/26 HER2CLIMB-05: Subgroup Analyses of Tucatinib,
Trastuzumab & Pertuzumab in HER2+ mBC
VJOncology 6/8/26 Optimizing Sequencing & Maintenance Strategies in HER2+
Metastatic Breast Cancer
VUMEDI 6/8/26 ASCO® 2026 Insights: HER2-Positive mBC 1L
Maintenance - HER2CLIMB-05 Tucatinib + HP Trial Data
and Practice Implications
VUMEDI 6/8/26 ASCO® 2026 Highlights: Breast Cancer - Integrating IO,
Oral SERDs, and ADCs Into 1L Care
Continued ➔
